HC Wainwright & Co. Reinstates Buy on Aldeyra Therapeutics, Announces $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Matthew Caufield reinstates a Buy rating on Aldeyra Therapeutics (NASDAQ:ALDX) with a $10 price target.
April 02, 2024 | 12:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aldeyra Therapeutics reinstated with a Buy rating and a $10 price target by HC Wainwright & Co.
The reinstatement of a Buy rating and the setting of a $10 price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the stock, suggesting potential upside. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100